ArticlePituitary2026
Co-secretion of growth hormone and prolactin defines a high-risk acromegaly phenotype.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundData on GH and prolactin (PRL) co-secreting pituitary neuroendocrine tumors (GH/PRL-PitNETs), a subtype of acromegaly, remain limited. In particular, comparative analyses of clinical outcomes, including remission rates, between GH/PRL-PitNETs and GH-secreting pituitary neuroendocrine tumors (GH-PitNETs) are scarce.
objectiveThis study aimed to characterize and compare the clinical course and remission outcomes of GH/PRL-PitNETs and GH-PitNETs.
methodsWe retrospectively analyzed 188 patients with acromegaly who underwent surgery between 2018 and 2024. GH/PRL-PitNETs (n = 46) were compared with GH-PitNETs (n = 142) in terms of their clinical, biochemical, and radiological features. Kaplan-Meier analysis was used to assess differences in biochemical remission between the groups, after which Cox proportional hazards modeling-including a time-dependent treatment variable-was used to identify covariates independently associated with remission.
resultsGH/PRL-PitNETs were significantly larger and more invasive than GH-PitNETs. The surgical remission rate was lower in the GH/PRL-PitNET group (P = .023). In multivariable Cox analysis, tumor size and cavernous sinus invasion independently predicted inferior outcome in biochemical remission. GH-PitNETs showed a higher incidence of medical comorbidities such as hypertension and thyroid carcinoma.
conclusionGH/PRL-PitNETs demonstrated greater tumor burden and more pronounced structural invasiveness, resulting in a significantly lower likelihood of endocrinological remission.
Indexed as
Identifiers
42315804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.